Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-10-18
2005-10-18
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S235800, C514S236200, C544S111000, C544S121000, C544S122000, C544S129000
Reexamination Certificate
active
06956037
ABSTRACT:
The invention concerns amide derivatives of Formula (I), wherein R3is (1-6C)alkyl or halogeno; m is 1-3 and R1is selected from substituents such as: (A) hydroxy, halogeno, (1-6C)alkyl, (1-6C)alkoxy, aryl, heteroaryl and heterocyclyl; and (B) di-[(1-6C)alkyl]amino-(1-6C)alkyl, (1-6C)alkoxy-(2-6C)alkoxy, di-[(1-6C)alkyl]amino-(2-6C)alkoxy, aryloxy, heteroaryloxy, heteroaryl-(1-6C)alkoxy, heterocyclyloxy and heterocyclyl-(1-6C)alkoxy; p is 0-2 and R2is a substituent such as hydroxy and halogeno; q is 0-4; and R4is aryl or cycloalkyl which bears 1-3 substituents such as: (C) hydrogen, hydroxy, halogeno and heterocyclyl; and (D) heteroaryl-(1-6C)alkoxy and heterocyclyl-(1-6C)alkoxy, provided that a substituent on R4is selected from paragraph (C) only if at least one R1group is selected from paragraph (B); processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
REFERENCES:
patent: 1903899 (1933-04-01), Laska et al.
patent: 1909960 (1933-05-01), Hitch
patent: 3211555 (1965-10-01), Mory et al.
patent: 3755332 (1973-08-01), Wasley et al.
patent: 4367328 (1983-01-01), Bertram et al.
patent: 4524168 (1985-06-01), Wick
patent: 4749729 (1988-06-01), Kohli et al.
patent: 6579872 (2003-06-01), Brown et al.
patent: 522 788 (1931-03-01), None
patent: 28 12 252 (1979-10-01), None
patent: 0 635 507 (1995-01-01), None
patent: 0 849 256 (1998-06-01), None
patent: 50105558 (1975-08-01), None
patent: 93/04170 (1993-03-01), None
patent: 95/19774 (1995-07-01), None
patent: 97/05878 (1997-02-01), None
patent: 97/13771 (1997-04-01), None
patent: 97/32853 (1997-09-01), None
patent: 98/06715 (1998-02-01), None
patent: 98/22103 (1998-05-01), None
patent: 99/15164 (1999-04-01), None
patent: 99/59959 (1999-11-01), None
patent: 99/59960 (1999-11-01), None
patent: 00/07980 (2000-02-01), None
patent: 00/07991 (2000-02-01), None
patent: 00/18738 (2000-04-01), None
patent: 00/20402 (2000-04-01), None
Adams et al., “Search for trypanocides. III. Analogs of suramin.”, Chemical Abstracts, vol. 51, 1957, cols. 5068 and 5069.
Ando et al., “Producing azo lake pigments”; Chemical Abstract, vol. 106, Abstract No., 215574, Aug. 30, 1988.
Ando et al., “Substitutent Shielding Parameters of Ffluorine-19 NMR on Polyfluoroaromatic Compounds Dissolved in Dimethyl Sulfoxide-d6”, Magn. Reson.Chem. 639-45, 1995, Chemical Abstract: 123: 227514, 1995.
Ashton et al., “New Low-Density Lipoprotein Receptor Upregulators Acting via a Novel Mechanism”, J. Med. Chem., 1996, vol. 39, pp. 3343-3356.
Beilstein Reg. No. 2164595, 1989.
Beilstein Reg. No. 3166971, 1990.
Beilstein Reg. No. 3451759, 1990.
Beilstein Reg. No. 3480574, 1990.
Beilstein Reg. No. 3483669, 1990.
Beilstein Reg. No. 3534091, 1990.
Chemical Abstract No. 12076g, vol. 65, 1966.
Chemical Abstract No. 12932a, vol. 51, 1957.
Denny et al., “Potential Antitumour Agents. 29. Quantitative Structure-Activity Relationships for the Antileukemic Bisquaternary Ammonium Heterocycles”, Journal of Medicinal Chemistry, Feb. 1979, vol. 22, No. 2, pp. 134-150.
Hamuro et al., “Novel Folding Patterns in a Family of Oligoanthranilamides: . . . Secondary Structures”, J. Amer. Chem. Soc., 1997, pp. 10587-10593.
Ito et al., Photosensitive material containing microencapsulated hydrazine derivatives; Chemical Abstract, vol. 118, Abstract No. 70021, Jun. 1992.
Kelley et al., “Antirhinorvirus Activity of 6-Anilino-9-benxyl-2-chloro-9H-purines”, J. Med. Chem., 1990, vol. 33, pp. 1360-1363, XP-002140324.
Lesiak, “New amides of pyrrole-N- and indole-N-caboxylic acids”, Chemical Abstracts, No. 126704v, XP-002121335, 1971.
Makoto; “Amide and Its Use”; Patent Abstracts of Japan, Abstract No. 09124571, May 13, 1997, also attached: Abstract (Derwent); XP 002086154.
Mühlbach, “Pyrazoles—A Novel Class of Blocking Agents for Isocyanates”, Journal of Polymer Science: Part A: Polymer Chemistry, vol. 32, Mar. 1994, pp. 753-765.
Myers et al., “The Preparation and SAR of 4-(Anilino), 4-(Phenoxy), and 4-(Thiophenoxy)-Quinazoline: Inhibitors of P56lckand EGF-R Tyrosine Kinase Activity”; Bioorganic & Medicinal Chemistery Letters, vol. 7, No. 4, pp. 417-420, 1997.
Petrova et al., “Determination of the Structure of the Oxidative . . . by Spectroscopic Methods”, Journal of Molecular Structure, vol. 142, 1986, pp. 459-462.
Sugawara et al., Kogyo Kaguku Zasshi 72(11) 2425-2429, 1969, Chemical Abstract: 72:66514, 1970.
Thompson et al., “Tyrosine Kinase Inhibitors. 7.7-Amino-4-(phenylamino- and 7-Amino-4-[(phenylmethyl)amino]purido4,3-dpyrimidines: A New Class of Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor”; Journal of Medicinal Chemistry, US, American Chemical Society, vol. 38, No. 19, 1995, pp. 3780-3788, XP002140323.
Wang et al., “Low-valent Titanium-induced Reactions of Substituted Nitrobenzenes”, J. Chem. Research, 1998, pp. 182-183.
Hanson, “Review—Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis- Inhibitors of p38 kinase”, Exp. Opin. Ther. Patents, 1997, XP-002086152, pp. 729-733.
Brown Dearg S
Brown George R
AstraZeneca AB
Morgan & Lewis & Bockius, LLP
Saeed Kamal A.
LandOfFree
Benzamide derivatives for the treatment of diseases mediated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzamide derivatives for the treatment of diseases mediated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzamide derivatives for the treatment of diseases mediated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3435906